Welcome to our dedicated page for Atyr Pharma SEC filings (Ticker: ATYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The aTyr Pharma, Inc. (Nasdaq: ATYR) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical stage biotechnology company focused on tRNA synthetase biology and therapies for fibrosis and inflammation, aTyr uses its filings to report on financial performance, clinical milestones and other material events related to its programs.
Investors can use this page to access current and historical reports such as Form 8-K filings, which aTyr has used to announce items like topline results from the Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis and quarterly financial results. These documents provide detail on study outcomes, including primary and secondary endpoints, safety observations and the company’s stated plans to engage with the U.S. Food and Drug Administration regarding the path forward for efzofitimod.
In addition to event-driven reports, this page is the gateway to aTyr’s periodic filings on Forms 10-K and 10-Q, where the company discusses its tRNA synthetase discovery platform, clinical pipeline, risk factors and financial statements. For a biotechnology issuer, these filings are central to understanding research and development spending, cash resources, and the status of key programs in interstitial lung disease and pulmonary fibrosis.
Stock Titan enhances access to these materials with AI-powered summaries that highlight important points from lengthy filings, helping readers quickly identify items such as trial results, changes in cash runway, or updates to development plans. Users can also review insider transaction filings on Form 4, as they become available through EDGAR, to monitor equity activity by directors and officers. Together, these resources offer a structured view of aTyr Pharma’s regulatory record and the disclosures that shape the ATYR investment narrative.
aTyr Pharma is a clinical-stage biotechnology company developing therapies for fibrosis and inflammation based on extracellular tRNA synthetase biology. Its lead drug, efzofitimod, targets interstitial lung diseases such as pulmonary sarcoidosis and systemic sclerosis-associated ILD.
A global Phase 3 sarcoidosis trial (EFZO-FIT) did not meet its primary endpoint of reducing oral steroid use versus placebo, but showed nominal improvements in quality-of-life measures and fatigue, with stable lung function and a generally favorable safety profile. The company plans a Type C FDA meeting in April 2026 to discuss a regulatory path.
aTyr is also running the EFZO-CONNECT Phase 2 trial in SSc-ILD, has an orphan/Fast Track regulatory portfolio, and a discovery platform with preclinical candidates ATYR0101 and ATYR0750 for fibrotic and inflammatory diseases. It remains pre-commercial, has a Japanese partnership with Kyorin, and highlights significant ongoing losses, funding needs and clinical, regulatory and market risks.
aTyr Pharma reported fourth quarter and full year 2025 results and provided a pipeline update centered on its lead drug efzofitimod for interstitial lung diseases.
The Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint of reducing mean daily oral corticosteroid dose at week 48, but the 5.0 mg/kg dose showed clinical benefits on several pre-specified measures of symptoms and quality of life, and maintained lung function with a favorable safety profile. The company has a Type C meeting with the FDA scheduled for mid-April 2026 to review the data and determine the regulatory path forward.
aTyr’s Phase 2 EFZO-CONNECT trial in systemic sclerosis-related interstitial lung disease is on track to complete enrollment in the first half of 2026. The company also highlighted preclinical progress for ATYR0101 in fibrosis and published research on a bispecific NRP2/PLXNA1 antibody with potential anticancer activity. For 2025, aTyr generated $190 thousand in collaboration revenue, incurred $60.2 million in research and development expenses and $17.6 million in general and administrative expenses, leading to a net loss attributable to aTyr of $74.1 million, or $0.80 per share. Cash, cash equivalents, restricted cash and investments totaled $80.9 million as of December 31, 2025.
aTyr Pharma President and CEO Sanjay Shukla reported routine equity compensation activity. On February 3, 2026, 10,375 restricted stock units granted on February 3, 2022 vested and converted into the same number of common shares on a one-for-one basis.
On February 4, 2026, he sold 3,745 common shares at $0.976 per share to satisfy tax withholding obligations tied to this vesting. After these transactions, Shukla directly owned 153,553 shares of aTyr Pharma common stock. The RSU award vests in four equal annual installments from February 3, 2023 through February 3, 2026 and can vest earlier if he is terminated without cause following a change of control.
aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported routine equity compensation activity and a small share sale. On February 3, 2026, 3,750 restricted stock units vested and converted into the same number of common shares, originally granted on February 3, 2022.
On February 4, 2026, she sold 1,558 common shares at $0.976 per share to cover tax withholding obligations related to this RSU vesting. After these transactions, she directly held 37,296 shares of aTyr Pharma common stock, and no restricted stock units from this grant remained outstanding.
aTyr Pharma’s general counsel, Nancy Denyes, reported routine equity compensation activity and a small share sale. On February 3, 2026, 2,687 restricted stock units granted in 2022 vested and converted into the same number of common shares. On February 4, 2026, she sold 1,118 shares at $0.9761 per share to cover tax withholding tied to this RSU vesting. After these transactions, she directly owned 33,124 aTyr Pharma common shares.
aTyr Pharma Inc. reported an insider equity award to its President and CEO, Sanjay Shukla. On January 9, 2026, he was granted an employee stock option1,500,000 shares of common stock at an exercise price of $0.7127 per share. The Form 4 shows the transaction as acquired and held directly, with 1,500,000 derivative securities beneficially owned after the grant.
The option will vest in 36 equal monthly installments beginning February 9, 2026, and is expected to be fully exercisable by January 9, 2029. The award agreement also provides for accelerated vesting if Dr. Shukla is terminated without cause in connection with a change of control of the company.
aTyr Pharma’s Chief Financial Officer, Jill Marie Broadfoot, reported a grant of 412,500 Employee Stock Options on January 9, 2026. The options have an exercise price of $0.7127 per share and were granted at $0 cost, increasing her derivative holdings to 412,500 options.
According to the filing, these options vest in 36 equal monthly installments beginning February 9, 2026 and are scheduled to be fully exercisable on January 9, 2029, with potential accelerated vesting if she is terminated without cause following a change of control. After this grant, she beneficially owns 35,104 shares of common stock, including shares acquired through the company’s 2015 Employee Purchase Plan.
aTyr Pharma Inc.'s General Counsel, Nancy Denyes, reported a new equity award and current holdings. On January 9, 2026, she was granted 412,500 Employee Stock Options with an exercise price of $0.7127 per share. These options vest in 36 equal monthly installments beginning February 9, 2026, becoming fully exercisable on January 9, 2029, and are subject to accelerated vesting if she is terminated without cause in connection with a change of control of the company.
Following this grant, she beneficially owns 31,555 shares of aTyr Pharma common stock directly, which include 2,500 shares acquired on May 15, 2025 and 2,500 shares acquired on November 14, 2025 under the company’s 2015 Employee Purchase Plan.
aTyr Pharma (ATYR) reported Q3 2025 results showing continued investment in its pipeline and a larger loss as it advances efzofitimod. License and collaboration revenue was $190 thousand. Research and development expense rose to $22.1 million, and general and administrative expense was $4.8 million, leading to a net loss of $25.7 million (basic and diluted net loss per share $0.26).
Cash, cash equivalents and available-for-sale investments totaled $92.9 million as of September 30, 2025. Year-to-date, the company raised $66.4 million via its Jefferies at‑the‑market program, selling 13,887,177 shares at a weighted‑average price of $4.94. Operating cash use for the first nine months was $49.8 million. Shares outstanding were 97,986,634 as of September 30, 2025.
The company announced that the Phase 3 EFZO-FIT study in pulmonary sarcoidosis did not meet its primary endpoint, though nominal improvements were observed on certain symptom measures, and efzofitimod was generally well‑tolerated. Management plans to meet the FDA in the first quarter of 2026 to discuss a path forward. Two putative securities class action complaints were filed in October 2025; no liability has been recorded.
aTyr Pharma (ATYR) reported that it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the press release as Exhibit 99.1 to an Item 2.02 Form 8-K. The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act. The filing also lists Exhibit 104 for the cover page Inline XBRL data.